Literature DB >> 26803390

Predictive Value of Conventional Ultrasound and Contrast-Enhanced Ultrasound in Early Recurrence of Hepatocellular Carcinoma after Surgical Resection.

Yibin Wang1, Jintang Liao2, Wenjun Qi1, Lulu Xie1, Yueyi Li1.   

Abstract

The goals of the work described here were to study the pre-operative risk factors associated with early recurrence (ER) of hepatocellular carcinoma (HCC) after surgical resection and discuss the value of conventional ultrasound (US) and contrast-enhanced ultrasound (CEUS) in predicting ER of HCC, so as to provide more information for optimizing clinical treatment and improving prognosis. A retrospective analysis was conducted on 59 patients who underwent both US and CEUS examinations pre-operatively and surgical resection for HCC between December 2010 and January 2014 in our hospital. The patients' clinical data, laboratory examination data and ultrasonic imaging diagnostic data were collected. Univariate analysis and logistic regression analysis were performed to determine the independent risk factors for ER of HCC after surgical resection. Diagnostic values of independent risk factors in predicting ER were further evaluated. The 59 patients were divided into the ER group (27 cases) and ER-free group (32 cases). There were no significant differences in age and sex between the two groups (p > 0.05). Univariate analysis revealed that differences in pre-operative serum α-fetoprotein level ≥400 ng/mL (p = 0.008), tumor diameter ≥5 cm (p = 0.012), macroscopic vascular invasion (p = 0.040), "fast wash-out" enhancement pattern (p = 0.006) and inhomogeneous distribution of contrast agent (p = 0.031) statistically significantly differed between the two groups. Logistic regression analysis indicated that pre-operative serum AFP level ≥400 ng/mL (p = 0.024), tumor diameter ≥5 cm (p = 0.042) and "fast wash-out" enhancement pattern (p = 0.009) were independent risk factors for ER of HCC; macrovascular invasion (p = 0.095) and inhomogeneous distribution of contrast agent (p = 0.628) did not statistically significantly differ between two groups (p = 0.628). Predictive values of the independent risk factors were further evaluated. The sensitivity of a "fast wash-out" enhancement pattern in predicting ER of HCC post-operatively did not statistically differ from that of tumor diameter ≥5 cm (p > 0.05), whereas it was significantly higher than the sensitivities of the other predictive indexes (p < 0.05). A pre-operative serum α-fetoprotein level ≥400 ng/mL, tumor diameter ≥5 cm and "fast wash-out" enhancement pattern are independent risk factors for ER of HCC after surgical resection. In addition, the "fast wash-out" enhancement pattern could probably be used to screen populations at high risk of recurrence owing to its high sensitivity in predicting ER of HCC post-operatively. All these findings provide beneficial information for management of HCC.
Copyright © 2016 World Federation for Ultrasound in Medicine & Biology. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Contrast-enhanced ultrasound; Hepatocellular carcinoma; Recurrence; Risk factor; Ultrasound

Mesh:

Substances:

Year:  2016        PMID: 26803390     DOI: 10.1016/j.ultrasmedbio.2015.12.010

Source DB:  PubMed          Journal:  Ultrasound Med Biol        ISSN: 0301-5629            Impact factor:   2.998


  8 in total

1.  Contrast-enhanced ultrasound-based ultrasomics score: a potential biomarker for predicting early recurrence of hepatocellular carcinoma after resection or ablation.

Authors:  Hui Huang; Si-Min Ruan; Meng-Fei Xian; Ming-de Li; Mei-Qing Cheng; Wei Li; Yang Huang; Xiao-Yan Xie; Ming-de Lu; Ming Kuang; Wei Wang; Hang-Tong Hu; Li-Da Chen
Journal:  Br J Radiol       Date:  2021-11-29       Impact factor: 3.039

2.  Diagnostic role of contrast-enhanced ultrasonography versus conventional B-mode ultrasonography in cirrhotic patients with early hepatocellular carcinoma: a retrospective study.

Authors:  Yandong Jiang; Meng Zhang; Yanting Zhu; Dongxiao Zhu
Journal:  J Gastrointest Oncol       Date:  2021-10

3.  The value of contrast-enhanced ultrasound in predicting postoperative recurrence of hepatocellular carcinoma: A protocol for systematic review and meta-analysis.

Authors:  Jieying Fu; Jia Tang; Huan Luo; Wencui Wu
Journal:  Medicine (Baltimore)       Date:  2021-06-04       Impact factor: 1.817

4.  Irregular vascular pattern by contrast-enhanced ultrasonography and high serum Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein level predict poor outcome after successful radiofrequency ablation in patients with early-stage hepatocellular carcinoma.

Authors:  Hitomi Takada; Kaoru Tsuchiya; Yutaka Yasui; Natsuko Nakakuki; Nobuharu Tamaki; Shoko Suzuki; Hiroyuki Nakanishi; Jun Itakura; Yuka Takahashi; Masayuki Kurosaki; Yasuhiro Asahina; Nobuyuki Enomoto; Namiki Izumi
Journal:  Cancer Med       Date:  2016-10-17       Impact factor: 4.452

5.  A sensitive three monoclonal antibodies based automatic latex particle-enhanced turbidimetric immunoassay for Golgi protein 73 detection.

Authors:  Yanyan Xia; Han Shen; Yefei Zhu; Hongpan Xu; Zhiyang Li; Jin Si
Journal:  Sci Rep       Date:  2017-01-05       Impact factor: 4.379

6.  Improvement of diagnostic efficiency in distinguishing the benign and malignant thyroid nodules via conventional ultrasound combined with ultrasound contrast and elastography.

Authors:  Mei-Juan Liu; Yan-Ming Men; Yong-Lin Zhang; Yu-Xi Zhang; Hao Liu
Journal:  Oncol Lett       Date:  2017-05-24       Impact factor: 2.967

7.  Characterization of Focal Liver Lesions Indistinctive on B Mode Ultrasound: Benefits of Contrast-Enhanced Ultrasound.

Authors:  Yi Dong; Feng Mao; Jiaying Cao; Peili Fan; Wen-Ping Wang
Journal:  Biomed Res Int       Date:  2017-04-11       Impact factor: 3.411

8.  Preoperative color Doppler ultrasonography predicts early recurrence in AFP-positive hepatocellular carcinoma.

Authors:  Miao Chen; Duo Wang; Yuan Zhao; Dan-Mei Lu; Hong-Xue Li; Jun-Jie Liu; Hang Li
Journal:  Oncol Lett       Date:  2019-09-09       Impact factor: 2.967

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.